These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

796 related items for PubMed ID: 16160167

  • 1. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA.
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [Abstract] [Full Text] [Related]

  • 2. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y.
    Vaccine; 2008 Mar 25; 26(14):1742-50. PubMed ID: 18336962
    [Abstract] [Full Text] [Related]

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 4. Pathogenesis of and immunity to avian influenza A H5 viruses.
    Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM.
    Biomed Pharmacother; 2000 May 25; 54(4):178-87. PubMed ID: 10872716
    [Abstract] [Full Text] [Related]

  • 5. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.
    Arch Virol; 2006 May 25; 151(5):921-31. PubMed ID: 16292596
    [Abstract] [Full Text] [Related]

  • 6. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A, Imai M, Tashiro M, Odagiri T.
    Vaccine; 2007 May 04; 25(18):3554-60. PubMed ID: 17293015
    [Abstract] [Full Text] [Related]

  • 7. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH, Seo SU, Song JM, Lee CM, Kim HA, Seong BL.
    Vaccine; 2006 Mar 10; 24(11):1966-74. PubMed ID: 16343703
    [Abstract] [Full Text] [Related]

  • 8. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.
    Arch Virol; 2010 Apr 10; 155(4):535-44. PubMed ID: 20195654
    [Abstract] [Full Text] [Related]

  • 9. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T, Takada A, Iwatsuki-Horimoto K, Kawaoka Y.
    Vaccine; 2004 Jun 02; 22(17-18):2244-7. PubMed ID: 15149783
    [Abstract] [Full Text] [Related]

  • 10. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC, Johansson BE.
    Virology; 2005 Sep 01; 339(2):273-80. PubMed ID: 15996702
    [Abstract] [Full Text] [Related]

  • 11. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF, Glenn GM.
    Vaccine; 2013 Sep 13; 31(40):4305-13. PubMed ID: 23891795
    [Abstract] [Full Text] [Related]

  • 12. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Wang H, Zhang R, Chen Z.
    Biochem Biophys Res Commun; 2006 May 19; 343(4):1124-31. PubMed ID: 16580631
    [Abstract] [Full Text] [Related]

  • 13. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 14. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.
    Vaccine; 2011 Oct 26; 29(46):8330-7. PubMed ID: 21911027
    [Abstract] [Full Text] [Related]

  • 15. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.
    J Infect Dis; 2009 Feb 01; 199(3):405-13. PubMed ID: 19061423
    [Abstract] [Full Text] [Related]

  • 16. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookrung N, Tongtawe P, Channarong S, Chaicumpa W.
    Vaccine; 2010 Sep 24; 28(41):6765-77. PubMed ID: 20688037
    [Abstract] [Full Text] [Related]

  • 17. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 18. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H.
    Vaccine; 2008 Jan 24; 26(4):562-72. PubMed ID: 18164788
    [Abstract] [Full Text] [Related]

  • 19. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.
    Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J.
    Vaccine; 2008 Feb 13; 26(7):956-65. PubMed ID: 18164519
    [Abstract] [Full Text] [Related]

  • 20. A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens.
    Sakabe S, Sakoda Y, Haraguchi Y, Isoda N, Soda K, Takakuwa H, Saijo K, Sawata A, Kume K, Hagiwara J, Tuchiya K, Lin Z, Sakamoto R, Imamura T, Sasaki T, Kokumai N, Kawaoka Y, Kida H.
    Vaccine; 2008 Apr 16; 26(17):2127-34. PubMed ID: 18346824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.